AI-generated · cited to primary sources · not investment advice · How we research
Medtronic plc. (MDT) Stock Analysis
Our verdict on Medtronic plc. isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The separation remains active and the previously announced timeline has not been changed. The company continues to expect completion within 18 months of the May 2025 announcement, approximately November 2026. (3 in progress, 1 met across 4 tracked commitments)
“In May 2025, the Company announced its intent to separate the Diabetes business, with the intention to create a new independent, publicly traded company, MiniMed Group, Inc. (MiniMed). The separation is expected to be completed within 18 months of the initial announcement.”
The filing shows concrete progress on the cardiovascular pipeline and commercialization efforts. Affera Sphere-360 received CE Mark in January 2026, while Liberant was described as a planned market launch. The document does not establish a U.S. FDA approval or completed commercial launch for Liberant. (4 in progress across 4 tracked commitments)
“Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of, and commercialize the products within our pipeline, including the Liberant mechanical thrombectomy system and Affera Sphere-360 pulsed field ablation single-shot catheter.”
The filing provides concrete evidence of adoption for several targeted platforms, but not a quantified market-share or product-specific target. Growth was strong in electrophysiology and TAVR, while renal denervation and peripheral products contributed more modestly. (1 in progress across 1 tracked commitment)
“Continued acceptance, adoption, and growth of our innovative portfolio of products in the electrophysiology (EP) segment, including the PulseSelect pulsed field ablation system and the Affera mapping and ablation system with Sphere-9 catheter. ... Market acceptance and reimbursement for the Symplicity Spyral renal denervation system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. ... Continued acceptance and growth of the Onyx Frontier drug-eluting stent (DES) platform. ... Acceptance and growth of IN.PACT 018 drug-coated balloons (DCB).”
The cost-management program was still active. The quarter included $67 million of MiniMed-related restructuring, primarily employee termination benefits, and the liability ended at $93 million. (1 in progress across 1 tracked commitment)
“The restructuring activities include organizational realignments, workforce-related actions, and separation of duplicated shared services, locations, systems, and operational functions. Of the total actions, the Company anticipates that materially all of the charges will relate to employee termination benefits, with the potential for other charges to include contract termination costs and asset write-offs.”
No explicit forward-looking commitments were provided for EBITDA/PAT margin, market-share percentage, bed capacity or occupancy, ROE, ROCE, or a specific full-year revenue-growth target in this quarterly report.
“The Company’s forward-looking statements may include statements related to ... financial results and financial condition; ... competitive strengths and market positioning, including changes in market share and demand ...”
See the full cited Management analysis of Medtronic plc.
How durable is the business?
Financial flexibility improved modestly through stronger operating cash flow, although liquidity remained pressured by dividends, debt repayments, and share repurchases. Nine-month operating cash flow increased 5.3% and free cash flow increased 7.2%. Total debt declined slightly from $28.5 billion to $28.1 billion, while cash and cash equivalents fell from $2.218 billion to $1.147 billion. (1 shifted)
“Operating cash flow was $4,757 million versus $4,516 million; free cash flow was $3,341 million versus $3,116 million; total debt was $28.1 billion versus $28.5 billion.”
Diabetes was expanding in the reported period, with sales up 10% year over year from $686 million to $757 million, driven primarily by international adoption of MiniMed 780G and related sensors and consumables. The later baseline showed continued acceleration to 17% growth and a larger 8.6% revenue share, although the business is still planned for separation from Medtronic. (2 expanding, 1 exited, 1 shifted across 1 engine)
“Diabetes' net sales for the three months ended July 31, 2026 was $843 million, an increase of 17 percent ... driven by growth in the U.S. due to the commercial launch of MiniMed Flex with Simplera Sync and continued international growth due to the continued adoption of the MiniMed 780G AID system”
Medtronic designs and sells medical devices and related services across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, serving hospitals, clinics, physicians, distributors, and government healthcare programs worldwide; Diabetes is being separated but remains in reported results while Medtronic retains control.
“Medtronic is the leading global healthcare technology company — alleviating pain, restoring health, and extending life for millions of people around the world. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care, respiratory and monitoring solutions, and diabetes conditions.”
Medical Surgical generated $2.279 billion, equal to 23.4% of total quarterly sales. Revenue grew 10% year over year. Segment operating profit was $485 million, implying a 21.3% segment operating margin based on the disclosed figures. — Medical Surgical (23.4% revenue share)
“Net sales $ 2,279 ... Reportable segment operating profit $ 485”
International customers generated $4.850 billion in the quarter and grew 11% year over year. International sales slightly trailed U.S. sales in dollars, but remained nearly half of the company's revenue.
“U.S. ... Total net sales $ 4,906 $ 4,224 16 % ... International ... Total net sales $ 4,850 $ 4,354 11 %”
See the full cited Business Model analysis of Medtronic plc.
Where does growth come from?
International growth is outpacing U.S. growth, particularly in Cardiovascular and Diabetes. Total international sales rose 8% in the latest quarter versus 3% in the U.S., and 5% versus 4% over the first six months. This indicates a positive, relatively steady geographic expansion trend, with the latest quarter showing stronger international momentum. (5 accelerating across 5 signals, 1 leading indicator)
“Electrophysiology Therapies (EPT) net sales for the three months ended July 31, 2026 increased 30 percent as compared to the corresponding period in the prior fiscal year. The net sales increase was driven by Cardiac Ablation Solutions due to growth in the pulsed field ablation portfolio and Cardiac Rhythm Management due to growth in Cardiac Pacing Therapies and Defibrillation Solutions.”
The product-led growth pipeline remains active in Cardiovascular. FDA-cleared or recently approved products include Affera/Sphere-9 in late October 2024 and Evolut FX+ in March 2024, while management expects continued adoption of Micra, Aurora EV-ICD, PulseSelect, Sphere-9, Evolut FX+, Symplicity Spyral, and other platforms. Because the filing provides only one current-period product-pipeline snapshot, the trend is classified as new rather than accelerating. (3 new trend across 3 signals, 2 leading indicators)
“The Stealth AXiS surgical system received U.S. FDA approval for spinal procedures in February 2026, followed by expanded approval for cranial and ENT applications in March 2026. ... The Hugo RAS system received U.S. FDA clearance for use in urologic surgical procedures in December 2025.”
Cranial & Spinal Technologies growth improved from 5% over the six-month period to 7% in the latest quarter. This is an accelerating signal, supported by continued adoption of the AiBLE ecosystem, which bundles spine implants with imaging, navigation, robotics, and AI-assisted planning. (1 accelerating, 2 new trend, 2 steady across 5 signals)
“Cranial & Spinal Technologies (CST) net sales for the three months ended July 31, 2026 increased 13 percent as compared to the corresponding period in the prior fiscal year. The net sales increase was driven by the continued adoption of the AiBLE ecosystem of spine implants and enabling technology with growth in Core Spine and Neurosurgery.”
The CathWorks acquisition signal is not present in this filing. The 10-Q reports only $98 million of total acquisitions for the nine months and describes a small fiscal-year acquisition with $108 million of goodwill, but it does not identify CathWorks, a $718 million purchase price, or an April 20, 2026 closing date. No trajectory can be established for this signal. (2 discontinued, 2 new trend across 4 signals, 2 leading indicators)
“The acquisition expands the Interventional Cardiology division within the Cardiovascular Portfolio by aiming to transform how coronary artery disease is diagnosed and treated.”
Medical Surgical has shifted from the previously cited positive-growth framing to a flat-to-negative trajectory. Sales declined 2% in the latest quarter and were flat for the nine months. The deterioration is concentrated in stapling, general surgery, pulse oximetry, and airway products, partly offset by Advanced Energy. This is a clear reversal from growth. (1 reversing across 1 signal)
“The increase in net sales for the three months ended July 31, 2026 ... was driven primarily by growth in most businesses ... including an extra week occurring in the first fiscal month of the first fiscal quarter in 2027 with an estimated benefit to reported growth of approximately $570 million.”
See the full cited Future Growth analysis of Medtronic plc.
What could break the thesis?
Tariff and trade-policy changes could increase manufacturing and sourcing costs or disrupt product flows. Although refunds offset the reported impact this quarter, future tariff changes could still materially reduce earnings. [REGULATORY]
“Recent developments in global trade policy have introduced new uncertainties for our business. The U.S., China, and other jurisdictions have recently imposed or proposed additional tariffs on imported goods. While we are taking proactive steps to mitigate the effects of these tariffs, the evolving nature of international trade policy continues to present a risk to our cost structure and financial performance.”
Reported sales growth benefited materially from an extra fiscal week, foreign-exchange movements, acquisitions, and portfolio changes. This makes the quarter less representative of underlying recurring demand and raises the risk of a later growth slowdown. [DEMAND]
“The increase in net sales for the three months ended July 31, 2026, as compared to the corresponding period in the prior fiscal year, was driven primarily by growth in most businesses, as further described in the business sections below, including an extra week occurring in the first fiscal month of the first fiscal quarter in 2027 with an estimated benefit to reported growth of approximately $570 million and by impacts of foreign currency fluctuations.”
Demand for medical procedures may slow because of replacement-cycle issues, hospital budget pressure, or changes in standards of care. In bariatric surgery, pharmaceuticals are already pressuring U.S. procedure volumes, which could reduce demand for related devices. [DEMAND]
“Our ability to execute ongoing strategies addressing the pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S.”
The balance-sheet risk remained material but there was no triggering impairment in the older quarter. Medical Surgical carried $19.788 billion of goodwill, while total goodwill was $41.811 billion. No goodwill impairment was recognized. The filing provides no sensitivity cushion or fair-value headroom, and the later baseline still identifies Medical Surgical goodwill as a high-risk valuation area, so the risk remained high rather than resolved. (4 stable)
“Total debt at July 31, 2026 was $28.2 billion as compared to $28.0 billion at April 24, 2026. The increase in total debt was primarily driven by the increase in short-term borrowings.”
Pricing, product mix, inflation, tariffs, and foreign-exchange movements can compress margins. The company says gross product cost percentage was flat only because favorable pricing and cost reductions offset unfavorable mix, leaving limited room for further adverse cost or pricing changes. [MARGIN_COST] (+1 more risk)
“Cost of products sold as a percentage of net sales for the three months ended July 31, 2026 was flat as compared to the corresponding period in the prior fiscal year, which was primarily driven by favorable pricing and cost-down initiatives, partially offset by unfavorable mixes.”
See the full cited Risk analysis of Medtronic plc.
Medtronic plc. analysis by filing period
Read the full thesis on Medtronic plc.
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.